Clinical Trial Update: Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nimotuzumab in combination with cisplatin-vinorelbine for cervical cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Nimotuzumab (nimotuzumab)
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: El Kendi Pharmaceuticals Manufacturing Company | Conditions: Cervical Cancer | Phase 3 | Status: COMPLETED